Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-51

As long as the fundamentals stay strong, the current SP value will be irrelevant for us long term holders.

I do believe management made a major error in the last CR by heavily discounting the SP. However this error of judgement will not impact the end goal which is major $$$$$ for those that hold for that pay day.

Management have kicked shareholders in the guts but I'm still holding and continue to top up at these levels while it lasts.

Any positive announcement can also turn things around quickly.

But it does make me wonder why management heavily discounted the SP, I am speculating but management might not be interested in the SP as they may be focused on a buy out during phase 2 trials.

Time will only tell what will happen.